Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Typhoid Vi Polysaccharide Vaccine Market Expected To Become By 2029 Compared With Its 2025 Level?
The market size for the typhoid vi polysaccharide vaccine has seen rapid expansion over recent years. It is anticipated to increase from $5.78 billion in 2024 to $6.71 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.1%. This historical growth can be credited to factors such as disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, and the vaccine’s efficacy and safety.
The market for typhoid Vi polysaccharide vaccine is projected to experience substantial expansion over the coming years. This market is anticipated to reach $13.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 18.2%. The impetus for this growth during the forecast period stems from factors such as broadened immunization initiatives, heightened attention from global health policies, vigilant epidemiological surveillance, increasing requirements in travel medicine, and various environmental and social elements. Significant trends identified for the forecast period encompass investments in research and development, supportive regulatory frameworks, ongoing epidemiological investigations, and enhanced public health awareness.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp
Which Drivers Are Supporting Growth Of The Typhoid Vi Polysaccharide Vaccine Market?
The increasing prevalence of typhoid is anticipated to drive the expansion of the typhoid VI polysaccharide vaccine market. Typhoid is a potentially fatal infection caused by the bacteria Salmonella typhi, commonly transmitted through contaminated food or drink. The typhoid Vi polysaccharide vaccine is used to immunize adults and children aged 2 and up against typhoid fever caused by Salmonella enterica serovar Typhi, S. Typhi. For instance, in August 2024, data published by the UK Health Security Agency, a UK-based government agency, revealed an increase in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. Specifically, S. Typhi cases rose from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. This rising typhoid prevalence, therefore, fuels the growth of the typhoid VI polysaccharide vaccine market.
Which Key Segments Fueling The Typhoid Vi Polysaccharide Vaccine Market?
The typhoid vi polysaccharide vaccinemarket covered in this report is segmented –
1) By Type: Child; Adult
2) By Route Of Administration: Oral; Parenteral
3) By Application: Government Institution; Private Sector; Other Applications
Subsegments:
1) By Child: Pediatric Formulations; Age-Specific Dosages
2) By Adult: Standard Adult Formulations; High-Risk Population Formulations
Which Ongoing Trends Are Expected To Shape The Typhoid Vi Polysaccharide Vaccine Market Outlook?
Strategic alliances are emerging as a significant development within the typhoid Vi polysaccharide vaccine market. Major entities operating in the typhoid Vi polysaccharide vaccine market are forging collaborations to fortify their standing. For instance, in July 2022, The International Vaccine Institute, an international organization from South Korea dedicated to infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, established a partnership with Moderna, a US-based biopharmaceutical company. This collaboration produced the world’s first affordable oral cholera vaccine and a next-generation typhoid conjugate vaccine.
Which Key Market Players Are Investing In Expansion And Innovation Of Typhoid Vi Polysaccharide Vaccine Market?
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited
Download The Full Report For Exclusive Market Findings:
What Are The Key Regional Factors Influencing The Typhoid Vi Polysaccharide Vaccine Market Growth?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Typhoid Vi Polysaccharide Vaccine Market Report:
https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp
Browse Through More Reports Similar to the Global Typhoid Vi Polysaccharide Vaccine Market 2025, By The Business Research Company
Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Pediatric Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
Cancer Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model